Description

Oxlumo (Lumasiran) is a medication used to treat primary hyperoxaluria type 1 (PH1), a rare genetic disorder. Lumasiran acts by targeting and silencing the HAO1 gene mRNA, leading to a decrease in the production of the glycolate oxidase (GO) enzyme and reducing oxalate overproduction. It is a double-stranded small interfering ribonucleic acid (siRNA) and falls under the category of RNAi therapeutics. Healthcare providers prescribe Oxlumo as a subcutaneous injection to decrease oxalate levels in urine and blood, aiding in preventing kidney damage and other complications linked to PH1.

Directions

Oxlumo is typically administered as a subcutaneous injection, meaning the injection is given under the skin. The standard Oxlumo dosing schedule depends on the patient's body weight. Typically, patients will receive a higher loading dose at the beginning of treatment, followed by maintenance doses at a lesser frequency.

It's important that patients follow their healthcare provider's instructions on when and how to inject Oxlumo. They should also be aware that Oxlumo may cause side effects such as injection site reactions, and they should contact their healthcare provider if they have concerns or experience unusual symptoms.

Ingredients

Lumasiran Sodium is the main active ingredient in Oxlumo.

Contraindications

The drug label for Oxlumo does not contain any contraindications. However, individuals with a known hypersensitivity to Lumasiran or any of its components should avoid taking the medication.

Cautions

• Before using Oxlumo, ensure you provide your healthcare provider with the following information:
  • Existing health conditions
  • Known allergies
  • A list of all the medications you are currently taking
  • Your pregnancy or breastfeeding status
• Before using, check Oxlumo to ensure the solution is clear, colorless-to-yellow, and free from particles. Do not use it if it appears cloudy, discolored, or contains particles.
• Always use aseptic techniques to prevent contamination when administering Oxlumo.
• The effects of Oxlumo during pregnancy are not well understood. There is no human data available, but animal studies did not show harmful effects at high doses.
• It is unknown if Oxlumo passes into human breast milk or if it affects milk production. The benefits of breastfeeding should be considered along with the mother’s need for Oxlumo.
• Oxlumo is approved for use in pediatric patients from birth onwards, supported by clinical studies in children and adults, including those with advanced kidney disease.

Side Effects

The long-term data suggest that Oxlumo is well-tolerated over extended periods. Oxlumo's most frequently reported side effects involve reactions at the injection site, such as redness, swelling, pain, and itching. These are generally mild and tend to resolve quickly. Stomach pain of varying types has also been noted but occurs less frequently.

References:

1. Oxlumo (Lumasiran) Product Monograph. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; 2023.
2. Oxlumo (Lumasiran) Drug Label Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; 2023.

About Dr. Gerardo Sison (Page Author)

Dr. Sison graduated with honors from the University of Florida. He began his career in pharmacy counseling patients in a community setting and later served in hospitals and clinics. He has also worked in medication therapy management services. Read More....

Product Code : 13769